Welcome to our dedicated page for LeonaBio news (Ticker: LONA), a resource for investors and traders seeking the latest updates and insights on LeonaBio stock.
LeonaBio, Inc. (NASDAQ: LONA) is a clinical-stage biopharmaceutical company whose news flow centers on oncology and neurodegenerative disease drug development. The company reports that it is dedicated to advancing novel small molecule therapies for treatment-resistant metastatic breast cancer and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).
News about LeonaBio often highlights progress in its lead programs, lasofoxifene and ATH-1105. For oncology-focused readers, updates may include developments in the Phase 3 ELAINE-3 (NCT05696626) trial of lasofoxifene in combination with abemaciclib for ER+, HER2-negative, ESR1-mutated metastatic breast cancer. The company also references earlier Phase 2 studies, ELAINE-1 and ELAINE-2, which inform the ongoing late-stage program.
For those following neurodegenerative research, news can cover clinical milestones for ATH-1105, LeonaBio’s orally available, brain-penetrant small molecule designed to modulate the neurotrophic HGF system. This includes information on the completed first-in-human Phase 1 trial in healthy volunteers and plans for Phase 2 development in ALS.
Corporate and pipeline news may also address licensing transactions, such as LeonaBio’s exclusive global license (excluding Asia and certain Middle Eastern countries) for lasofoxifene from Sermonix Pharmaceuticals, Inc., as well as related private placement financings intended to support clinical and regulatory milestones. In addition, readers can find coverage of the company’s name change from Athira Pharma, Inc. to LeonaBio, Inc. and the adoption of the LONA ticker, which reflect its focus on late-stage oncology assets and a broader mission in serious diseases.
Investors, clinicians, and researchers can use this news feed to monitor key clinical trial updates, licensing and financing announcements, and corporate identity developments that shape LeonaBio’s pipeline and strategy.
LeonaBio (NASDAQ: LONA) highlighted independent nonclinical data on lasofoxifene at AACR Annual Meeting 2026 showing bone-protective effects and sustained anti-tumor activity in ER+ and ESR1-mutant metastatic breast cancer animal models. The data support the scientific rationale for the ongoing ELAINE-3 Phase 3 study.
Researchers reported lasofoxifene reduced metastatic bone tumor burden while preserving bone microenvironment integrity in preclinical models.
LeonaBio (NASDAQ: LONA) reported full-year 2025 results and a business update after licensing lasofoxifene and closing a $90 million private placement, with warrants potentially providing up to an additional $146 million. Cash and investments were $88.3M at year-end 2025.
The company expects to complete enrollment of its Phase 3 ELAINE-3 trial in 4Q 2026 with topline data anticipated in 2H 2027, and to initiate a Phase 2 ALS study of ATH-1105 in 2H 2026.
LeonaBio (NASDAQ: LONA) appointed Mark F. Kubik as Chief Business Officer effective Feb 3, 2026. Kubik brings more than 25 years of biopharma business development and corporate strategy experience and will lead licensing, partnerships, and corporate development.
He served as a strategic consultant and helped execute the December 2025 transformational transaction that gave LeonaBio rights to the Phase 3 lasofoxifene program for metastatic breast cancer. Management says Kubik will support advancing lasofoxifene in Phase 3 and expanding a diversified oncology and neurodegeneration pipeline.
Athira Pharma (NASDAQ: ATHA) changed its name to LeonaBio and will trade under new ticker LONA beginning January 12, 2026.
The name change follows a transformative exclusive license for lasofoxifene (Phase 3 ELAINE-3, >50% enrolled; topline data expected mid-2027) and an upfront private placement of $90 million plus warrants that could provide up to $146 million if fully exercised to fund development through key milestones into 2028.